Market Place
Sourcing Support
Odyssey Behavioral Healthcare Reports Improved Treatment Outcomes
16 Jul 2024 //
ACCESSWIRE
Odyssey Health Gains Shareholder Approval for Asset Sale with Oragenics, Inc.
12 Dec 2023 //
ACCESSWIRE
Odyssey Selects Syneos to Support NDA for Treatment of Concussion
16 Nov 2023 //
ACCESSWIRE
Oragenics to Acquire Odyssey’s Neurological Drug Technology Pipeline
05 Oct 2023 //
BUSINESSWIRE
Odyssey Health To Develop Intranasal Field- Deliverable Nerve Agent Antidote
12 Jan 2023 //
GLOBENEWSWIRE
Odyssey Provides a Year End Update on Company and Corporate Outlook for 2023
19 Dec 2022 //
GLOBENEWSWIRE
Odyssey Health Provides Update on Company and Drug Development
23 Nov 2022 //
GLOBENEWSWIRE
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma
03 Nov 2022 //
GLOBENEWSWIRE
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled
01 Nov 2022 //
GLOBENEWSWIRE
Odyssey Forms Pharmaceutical Subsidiary Focused on Neurological Diseases
11 Oct 2022 //
GLOBENEWSWIRE
Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Devp
30 Sep 2022 //
GLOBENEWSWIRE
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical
28 Sep 2022 //
GLOBENEWSWIRE
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug
18 Aug 2022 //
GLOBENEWSWIRE
Odyssey reports positive data from Phase I concussion trial
11 Aug 2022 //
CLINICALTRIALSARENA
Odyssey Announces Positive Results from Its PhI Dosing
10 Aug 2022 //
GLOBENEWSWIRE
Odyssey Health Successfully Completes PI Single Ascending Dosing
12 Jul 2022 //
GLOBENEWSWIRE
Odyssey Health Completes Safety Evaluation of Cohort II for Concussion Drug
29 Jun 2022 //
GLOBENEWSWIRE
Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug
01 Jun 2022 //
GLOBENEWSWIRE
Odyssey Therapeutics Appoints Industry Leader Jeffrey M. Leiden as Board Chair
19 May 2022 //
PRNEWSWIRE
Odyssey Health Announces Positive Results from Initial PI Trial
05 May 2022 //
GLOBENEWSWIRE
Odyssey Health Welcomes Timothy Szymanski to Military Advisory Board
20 Apr 2022 //
GLOBENEWSWIRE
Odyssey Group International Announces Formation of Military Advisory Board
31 Mar 2022 //
GLOBENEWSWIRE
Odyssey Group International Receives Donation for Treatment for Concussion
10 Jan 2022 //
GLOBENEWSWIRE
Odyssey Therapeutics Acquires Rahko, a Quantum Machine Learning Company
06 Jan 2022 //
PRNEWSWIRE
Odyssey Group International Approved to Start Human Trial to Treat Concussion
01 Sep 2021 //
GLOBENEWSWIRE
Odyssey Group Completes Drug-Device Combo Product for Clinical Trial Launch
30 Aug 2021 //
GLOBENEWSWIRE
Odyssey Group International and Super Bowl MVPs Featured on “Banfield”
06 Aug 2021 //
GLOBENEWSWIRE
Odyssey Group International Provides Notice of Annual Meeting of Stockholders
26 Jul 2021 //
GLOBENEWSWIRE
Odyssey Group Reports Achieving Drug Safety Standards for Clinical Trials
29 Jun 2021 //
GLOBENEWSWIRE
Odyssey Group Announces Successful Toxicology Studies for its Drug
26 May 2021 //
GLOBENEWSWIRE
Odyssey Group International Announces Completion of Novel Device
18 May 2021 //
GLOBENEWSWIRE
